Allogeneic bone marrow mesenchymal stem cell-derived exosomes alleviate human hypoxic AKI-on-a-Chip within a tight treatment window.
Sefa Burak ÇamEda Çiftci DedeNazlıhan GürbüzBülent AltunPetek KorkusuzPublished in: Stem cell research & therapy (2024)
The real-time potency assay and 3D gravity-driven microfluidic acute hypoxic PT injury platform precisely demonstrated the therapeutic performance window of allogeneic hBMMSC-Exos on ischemic AKI based on structural and functional cellular data. The novel standardized, non-invasive two-step system validates the cell-based personalized theragnostic tool in a real-time physiological microenvironment prior to safe and efficient clinical usage in nephrology.
Keyphrases
- bone marrow
- mesenchymal stem cells
- high throughput
- single cell
- acute kidney injury
- stem cell transplantation
- stem cells
- cell therapy
- umbilical cord
- endothelial cells
- circulating tumor cells
- liver failure
- blood brain barrier
- electronic health record
- hematopoietic stem cell
- induced pluripotent stem cells
- intensive care unit
- ischemia reperfusion injury
- combination therapy
- hepatitis b virus
- label free
- low dose
- oxidative stress